Patient P-03460

Synthetic patientONX-7 · Day 127 · 25–34 · M · baseline S11Open companion preview

Therapy response

Improving

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

88%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S11
Day 56 SC-12 recommended — Supportive Compound SC-12
Day 57 Patient accepted — Started SC-12 in the companion
Day 63 GI symptom burden −18% vs expected — Supportive Compound SC-12
Day 64 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 69 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 64.

Primary contributors, last 14 days

Toxicity+13
Nutritional resilience-9
Treatment adherence-6
GI instability+3
Inflammatory activity+2

What helped?

Supportive Compound SC-12Day 56
Result: symptom burden −18%

LIFE OS recommendation

GI Support Protocol GI-04

91%

probability of meaningful tolerance improvement

284 similar trajectories
82% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 31/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 63 and rising
- WearableSleep 5.2 h, below personal baseline
Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 60
Drug metabolism and exposure ↑20
- BloodToxicity index 54
Autonomic recovery ↓20
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3.1 · butyrate capacity 31/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 53 ms
Sleep: 5.8 h
Steps: 6,320
Resting HR: 67 bpm

Daily log: GI score 63, nutritional resilience 33, adherence 48.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03037	47%	S14	NP-02	improved	43
P-03323	46%	S14	GI-04	improved	48
P-03293	43%	S14	GI-04	no change	41
P-03430	42%	S14	SC-12	improved	45
P-03049	41%	S14	GI-04	improved	49
P-03345	41%	S14	SC-12	improved	56
P-03413	41%	S14	ME-01	improved	48
P-03341	39%	S14	NP-02	improved	49
P-03081	37%	S10	GI-04	improved	53
P-03390	37%	S14	ME-01	improved	41
P-03090	36%	S02	GI-04	improved	48
P-03030	35%	S14	NP-02	improved	43